Understand the source comparison
Best DSIP Dosage for Circadian Rhythm: Dosing Comparison
0.5–1mg CT12 (dark phase onset) Minimal phase shift; increased delta-wave activity in first sleep cycle but no lasting rhythm adjustment Acute sleep architecture studies unrelated to circadian function Pharmacol Biochem Behav (1988) 2–2.5mg CT12 (30–60 min bef
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 0.5–1mg
- CT12 (dark phase onset)
- Minimal phase shift; increased delta-wave activity in first sleep cycle but no lasting rhythm adjustment
- Acute sleep architecture studies unrelated to circadian function
- Pharmacol Biochem Behav (1988)
- 2–2.5mg
- CT12 (30–60 min before dark phase)
- Moderate phase advance (45–90 min); stable rhythm re-entrainment in 4–5 days post-disruption
- Standard circadian restoration protocol; jet lag or shift work models
- Peptides (1987); Eur J Pharmacol (1995)
- 5mg
- Maximal phase advance (90–120 min); no additional benefit beyond 2.5mg in most models
- High-disruption models (12+ hour phase shifts); subjects with low receptor density
- Chronobiol Int (1991)
- 10mg+
- Any timing
- Non-specific sedation; increased total sleep time without phase adjustment; obscures circadian-specific effects
- Not recommended for circadian research. Activates off-target pathways